BC Week In Review | Jan 26, 2015
Clinical News

Dutrebis lamivudine/raltegravir regulatory update

EMA’s CHMP recommended approval of Dutrebis lamivudine/raltegravir to treat HIV-1 infection in patients ages ³6 and weighing ³30 kg. According to CHMP, Dutrebis reduces the daily pill burden while retaining comparable efficacy to the individual...
Items per page:
1 - 1 of 1